Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

autism treatment

  • Home
  •  
  • autism treatment



  • Most Read
  • Latest Comments
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • News

  • Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    • News

  • Algorae teams up with HL Pharma to supply cannaboids for research projects
    Algorae teams up with HL Pharma to supply cannaboids for research projects
    • News

  • Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    • News

  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

    Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug

    Autism Spectrum Disorder (ASD) affects 1 in 150 Australians. Boys are 4 times more likely to have it than girls, and symptoms are noticeable at around 2-3 years of age. According to the Australian Institute of Health and Welfare, the number of people with ASD in Australia is increasing, providing an impetus for biopharmaceutical company

    Read More
    Public
  • Zelda to launch clinical trials testing cannabis as solution to insomnia
    • News

    Zelda to launch clinical trials testing cannabis as solution to insomnia

    Australian bio-pharmaceutical developer Zelda Therapeutics (ASX: ZLD) has now fully enrolled insomnia sufferers into clinical trials where the Company aims to use cannabis as a treatment for clinically diagnosed patients.  This set of trials will be completed in collaboration with the University of Western Australia (UWA) Centre for Sleep Science. The trials will aim to

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.